Nautilus Biotechnolgy
NAUT
88 hedge funds and large institutions have $107M invested in Nautilus Biotechnolgy in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 17 reducing their positions, and 11 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 17
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
6% more funds holding
Funds holding: 83 → 88 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.32% less ownership
Funds ownership: 51.18% → 50.87% (-0.32%)
41% less capital invested
Capital invested by funds: $183M → $107M (-$75.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$337K |
| 2 |
JP Morgan Chase
New York
|
+$264K |
| 3 |
WC
Wexford Capital
West Palm Beach,
Florida
|
+$232K |
| 4 |
Renaissance Technologies
New York
|
+$228K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$187K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.19M |
| 2 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$576K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$449K |
| 4 |
CC
Clearline Capital
New York
|
-$411K |
| 5 |
ST
Sentinel Trust
Houston,
Texas
|
-$144K |
NAUT Hedge Fund Activity: Q4 2024 in Review
88 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Nautilus Biotechnolgy (NAUT) for Q4 2024, worth a combined $107M — down 41% from $183M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new NAUT positions and 11 closed out — a net gain of 5 holders — while 26 added to existing stakes and 17 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $337K. The largest seller was BlackRock, cutting an estimated $1.19M.
- 88 institutional investors held Nautilus Biotechnolgy (NAUT) as of Q4 2024, up from 83 in Q3 2024.
- Funds reported $107M of Nautilus Biotechnolgy stock for Q4 2024, down 41% quarter-over-quarter.
- 16 funds opened new Nautilus Biotechnolgy positions in Q4 2024 and 11 closed out, a net change of +5 holders.
- The largest Nautilus Biotechnolgy buyer in Q4 2024 was Citadel Advisors, an estimated $337K added.
- The largest Nautilus Biotechnolgy seller in Q4 2024 was BlackRock, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2024.